Premium
Humoral Immune Response to a Yeast‐derived Hepatitis B Vaccine in Patients with Type 1 Diabetes Mellitus
Author(s) -
Bouter K.P.,
Diepersloot R.J.A.,
Wismans P.J.,
Meyling F.H.J. Gmelig,
Hoekstra J.B.L.,
Heijtink R.A.,
Hattum J.
Publication year - 1992
Publication title -
diabetic medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 145
eISSN - 1464-5491
pISSN - 0742-3071
DOI - 10.1111/j.1464-5491.1992.tb01717.x
Subject(s) - medicine , diabetes mellitus , immune system , titer , gastroenterology , hepatitis b , vaccination , hepatitis b vaccine , immunology , hepatitis b virus , antibody , endocrinology , virus , hbsag
The immune response following vaccination with a recombinant hepatitis B vaccine was investigated in 32 patients with Type 1 diabetes mellitus and compared with the outcome in 32 healthy age‐ and sex‐matched volunteers. Participants were vaccinated at 0, 30, and 180 days and in vivo immune response was determined at 30, 60, 90, 180, and 210 days. The number of responders (anti‐HBs > 1 IU I −1 ) was significantly lower ( p < 0.05) among patients at 30 (2 vs 11), 60 (17 vs 26), 90 (20 vs 28) and 180 (22 vs 29) days. The number of patients protected (anti‐HBs > 10 IU I −1 ) was lower ( p < 0.05) than the number of protected volunteers at 60 (5 vs 14), 90 (10 vs 19), 180 (15 vs 24), and 210 days (24 vs 31). After the complete course of vaccination 8 out of 32 patients were still unprotected against hepatitis B ( p < 0.05). The anti‐HBs titre of responders at 210 days was 251 (20, 3162) (geometric mean (‐SD, +SD)) IU I −1 in patients and 1259 (126, 12589) IU I −1 in control subjects ( p < 0.05). The HLA‐antigen DQw1 frequency in the diabetic low responders (anti‐HBs < 100 IU I −1 ) was 0.27 compared with 0.86 in diabetic adequate responders. No relation between anti‐HBs production and concentration of HbA 1c could be demonstrated.